Switch to abacavir-based triple nucleoside regimens in HIV-1 infected patients never treated with suboptimal antiretroviral therapy: a review.

Abstract excerpt

The major trials conducted on treatment simplification included large portions of patients who had previously received monotherapy or dual therapy and were likely to have relevant mutations of resistance at baseline. These studies concluded that simplification was safe (especially when this population was excluded), with some additional risk of viral failure for subjects simplified to abacavir-based regimens. On...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Anti-HIV Agents
• Share to Antiretroviral Therapy, Highly Active